Organizing pneumonia as a side effect of ipilimumab treatment of melanoma Journal Article

Authors: Barjaktarevic, I. Z.; Qadir, N.; Suri, A.; Santamauro, J. T.; Stover, D.
Article Title: Organizing pneumonia as a side effect of ipilimumab treatment of melanoma
Abstract: Ipilimumab is one of the newly developed human monoclonal antibodies used in the treatment of metastatic melanoma. Its primary mechanism of action is a specific blockade of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a T-cell receptor responsible for inhibition of lymphocyte activation. By blocking CTLA-4, ipilimumab enhances immune responses against tumor cells, but also exposes normal tissues to an increased risk of autoimmune phenomena as a potential side effect. In this report, we describe the case of a 58-year-old woman with metastatic melanoma who was treated with ipilimumab in the weeks prior to the onset of severe nonresolving dyspnea and cough. Extensive workup revealed organizing pneumonia as the cause of her hypoxemic respiratory failure and treatment with steroids led to a resolution of her pulmonary disease. To our knowledge, this is the first report of pulmonary toxicity caused by ipilimumab, which manifested on pathology as organizing pneumonia. © 2013 American College of Chest Physicians.
Journal Title: Chest
Volume: 143
Issue: 3
ISSN: 0012-3692
Publisher: American College of Chest Physicians  
Date Published: 2013-03-01
Start Page: 858
End Page: 861
Language: English
DOI: 10.1378/chest.12-1467
PROVIDER: scopus
PUBMED: 23460165
Notes: --- - "Export Date: 1 April 2013" - "CODEN: CHETB" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Anu Suri
    1 Suri